UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
November 13, 2009
Artepharm Global Corp.
Nevada
|
333-153354
|
98-0460379
|
Suite #222, 6820 188th Street
(Address of principal executive offices) |
|
V4N 3G6
|
(604) 575-3552
Registrant's telephone number, including area code
Former Name: Blackrock Resources Inc.
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Effective under Nevada corporate law as of November 13, 2009, the Company filed a Certificate of Amendment to its Articles of incorporation to change its name to "Artepharm Global Corp." and to increase its authorized share capital from 75,000,000 shares (with a par value of $0.001 per share) to 500,000,000 shares (with the par value unchanged at $0.001 per share).
In connection with this name change to Artepharm Global Corp., the Company was assigned the following new CUSIP number and trading symbol on January 14, 2010:
New CUSIP Number: 04302G101
New Trading Symbol: ARGC
Item 9.01 Financial Statements and Exhibits
(a) Financial Statements of Business Acquired
Not applicable.
(b) Pro forma Financial Information
Not applicable.
(c) Shell Company Transaction
Not applicable.
(d) Exhibits
Exhibit |
Description |
3.1 |
Certificate of Amendment as filed with the Nevada Secretary of State, effective as of November 13, 2009. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: March 3, 2010 |
ARTEPHARM GLOBAL CORP.
"Harpreet S. Sangha"
|
__________